Assignee
BIOMARIN PHARM INC
US·107 granted patents·87 pending applications·1,053 citations·filing 2000–2025
Top patents by PatentIndex Score
194 records- 0198US7531341B1Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereofBIOMARIN PHARM INC·Filed 2006·Granted May 12, 2009·87 cites·6 claims
- 0297US7981864B2Methods and compositions for targeting proteins across the blood brain barrierBIOMARIN PHARM INC·Filed 2008·Granted Jul 19, 2011·23 cites·8 claims
- 0397US7534595B2Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereofBIOMARIN PHARM INC·Filed 2007·Granted May 19, 2009·79 cites·34 claims
- 0497US7442372B2Delivery of therapeutic compounds to the brain and other tissuesBIOMARIN PHARM INC·Filed 2003·Granted Oct 28, 2008·109 cites·49 claims
- 0596US9993481B2Methods and compositions for the treatment of metabolic disordersBIOMARIN PHARM INC·Filed 2016·Granted Jun 12, 2018·11 cites·20 claims
- 0696US9504762B2Adeno-associated virus factor VIII vectorsBIOMARIN PHARM INC·Filed 2014·Granted Nov 29, 2016·28 cites·9 claims
- 0796US8012976B2Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)BIOMARIN PHARM INC·Filed 2009·Granted Sep 6, 2011·40 cites·5 claims
- 0896US7560263B2Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereofBIOMARIN PHARM INC·Filed 2008·Granted Jul 14, 2009·81 cites·26 claims
- 0996US7537923B2Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereofBIOMARIN PHARM INC·Filed 2008·Granted May 26, 2009·49 cites·9 claims
- 1095US7566714B2Methods and compositions for the treatment of metabolic disordersBIOMARIN PHARM INC·Filed 2005·Granted Jul 28, 2009·15 cites·46 claims
- 1194US9834587B2Targeted therapeutic lysosomal enzyme fusion proteins and uses thereofBIOMARIN PHARM INC·Filed 2015·Granted Dec 5, 2017·6 cites·12 claims
- 1294US9834588B2Targeted therapeutic lysosomal enzyme fusion proteins and uses thereofBIOMARIN PHARM INC·Filed 2015·Granted Dec 5, 2017·7 cites·12 claims
- 1394US9814762B2Targeted therapeutic proteinsBIOMARIN PHARM INC·Filed 2016·Granted Nov 14, 2017·6 cites·24 claims
- 1494US9340822B2Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarkerBIOMARIN PHARM INC·Filed 2014·Granted May 17, 2016·12 cites·23 claims
- 1594US8809009B2Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarkerBIOMARIN PHARM INC·Filed 2012·Granted Aug 19, 2014·14 cites·16 claims
- 1694US7790433B2Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereofBIOMARIN PHARM INC·Filed 2009·Granted Sep 7, 2010·32 cites·6 claims
- 1793US10301369B2Nucleic acids encoding targeted therapeutic lysosomal enzyme fusion proteinsBIOMARIN PHARM INC·Filed 2017·Granted May 28, 2019·5 cites·17 claims
- 1893US9512143B2Histone deacetylase inhibitorsBIOMARIN PHARM INC·Filed 2015·Granted Dec 6, 2016·11 cites·18 claims
- 1992US10646550B2Use of C-type natriuretic peptide variants to treat skeletal dysplasiaBIOMARIN PHARM INC·Filed 2018·Granted May 12, 2020·7 cites·13 claims
- 2092US10300113B2Targeted therapeutic proteinsBIOMARIN PHARM INC·Filed 2017·Granted May 28, 2019·3 cites·17 claims
- 2192US9915649B2Methods of determining the presence, identity, and/or severity of mucopolysaccharidosis (MPS) VI and IVABIOMARIN PHARM INC·Filed 2016·Granted Mar 13, 2018·4 cites·34 claims
- 2292US9771408B2Targeted therapeutic lysosomal enzyme fusion proteins and uses thereofBIOMARIN PHARM INC·Filed 2015·Granted Sep 26, 2017·4 cites·12 claims
- 2392US9222120B2Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or conditionBIOMARIN PHARM INC·Filed 2014·Granted Dec 29, 2015·13 cites·21 claims
- 2491US11351231B2Lysosomal targeting peptides and uses thereofBIOMARIN PHARM INC·Filed 2017·Granted Jun 7, 2022·3 cites·7 claims
- 2591US10512675B2Adeno-associated virus factor VIII vectors, associated viral particles and therapeutic formulations comprising the sameBIOMARIN PHARM INC·Filed 2016·Granted Dec 24, 2019·9 cites·25 claims
- 2691US9845346B2Targeted therapeutic lysosomal enzyme fusion proteins and uses thereofBIOMARIN PHARM INC·Filed 2015·Granted Dec 19, 2017·4 cites·12 claims
- 2791US9557340B2Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyaseBIOMARIN PHARM INC·Filed 2015·Granted Jan 31, 2017·7 cites·14 claims
- 2891US9469683B2Lysosomal targeting peptides and uses thereofBIOMARIN PHARM INC·Filed 2014·Granted Oct 18, 2016·12 cites·5 claims
- 2991US9376480B2Targeted therapeutic lysosomal enzyme fusion proteins and uses thereofBIOMARIN PHARM INC·Filed 2013·Granted Jun 28, 2016·6 cites·21 claims
- 3091US7612073B2Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuringBIOMARIN PHARM INC·Filed 2008·Granted Nov 3, 2009·16 cites·11 claims
- 3191US6569661B1Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereofBIOMARIN PHARM INC·Filed 2000·Granted May 27, 2003·63 cites·10 claims
- 3290US11254725B2Targeted therapeutic lysosomal enzyme fusion proteins and uses thereofBIOMARIN PHARM INC·Filed 2019·Granted Feb 22, 2022·2 cites·13 claims
- 3390US9677116B2Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or conditionBIOMARIN PHARM INC·Filed 2015·Granted Jun 13, 2017·4 cites·30 claims
- 3490US9572870B2Delivery of therapeutic compounds to the brain and other tissuesBIOMARIN PHARM INC·Filed 2015·Granted Feb 21, 2017·6 cites·16 claims
- 3590US8377884B2Variants of C-type natriuretic peptidesBIOMARIN PHARM INC·Filed 2008·Granted Feb 19, 2013·27 cites·24 claims
- 3690US7566462B2Stable tablet formulationBIOMARIN PHARM INC·Filed 2008·Granted Jul 28, 2009·26 cites·20 claims
- 3789US10934534B2Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereofBIOMARIN PHARM INC·Filed 2020·Granted Mar 2, 2021·2 cites·29 claims
- 3889US9908899B2Histone deacetylase inhibitorsBIOMARIN PHARM INC·Filed 2016·Granted Mar 6, 2018·5 cites·24 claims
- 3989US8859498B2Targeted therapeutic proteinsBIOMARIN PHARM INC·Filed 2013·Granted Oct 14, 2014·3 cites·20 claims
- 4089US8003126B2Stable tablet formulationBIOMARIN PHARM INC·Filed 2005·Granted Aug 23, 2011·22 cites·22 claims
- 4188USRE48267EVariants of C-type natriuretic peptideBIOMARIN PHARM INC·Filed 2017·Granted Oct 20, 2020·2 cites·76 claims
- 4288US10260084B2Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or conditionBIOMARIN PHARM INC·Filed 2017·Granted Apr 16, 2019·2 cites·12 claims
- 4388US8999987B2Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)BIOMARIN PHARM INC·Filed 2013·Granted Apr 7, 2015·8 cites·23 claims
- 4488US7947681B2Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuringBIOMARIN PHARM INC·Filed 2009·Granted May 24, 2011·10 cites·28 claims
- 4588US7553653B2Variants and chemically-modified variants of phenylalanine ammonia-lyaseBIOMARIN PHARM INC·Filed 2005·Granted Jun 30, 2009·34 cites·7 claims
- 4687US10563183B2Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereofBIOMARIN PHARM INC·Filed 2018·Granted Feb 18, 2020·4 cites·18 claims
- 4787US7722865B2Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereofBIOMARIN PHARM INC·Filed 2009·Granted May 25, 2010·15 cites·20 claims
- 4887US7354576B2Methods of treating diseases caused by deficiencies of recombinant α-L-iduronidaseBIOMARIN PHARM INC·Filed 2004·Granted Apr 8, 2008·20 cites·11 claims
- 4986US9796664B2Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitorsBIOMARIN PHARM INC·Filed 2016·Granted Oct 24, 2017·5 cites·19 claims
- 5086US9018201B2Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiencyBIOMARIN PHARM INC·Filed 2013·Granted Apr 28, 2015·8 cites·21 claims
Showing the top 50 of 194 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when BIOMARIN PHARM INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →